A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-08

AUTHORS

Kim N. Chi, Stephen K. Chia, Ross Dixon, Michael J. Newman, Vince J. Wacher, Branimir Sikic, Karen A. Gelmon

ABSTRACT

BACKGROUND: ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg. METHODS: Phase I pharmacokinetic trial of ONT-093 in doses from 300 to 500 mg administered before and after intravenous paclitaxel doses of 150 to 175 mg/m(2) repeated every 21 days. All patients received paclitaxel alone on cycle 1. RESULTS: 18 patients were enrolled onto 4 dose levels. Toxicity of the combination included neutropenia, arthralgia, myalgia, and peripheral neuropathy. Four of 6 patients receiving 500 mg doses of ONT-093 and paclitaxel at 175 mg/m(2) (dose level 4) had higher-grade neutropenia with cycle 2, with 1 patient experiencing febrile neutropenia. Plasma pharmacokinetic parameters of paclitaxel were unchanged between cycle 1 and 2 for dose levels 1 to 3, but at dose level 4, 45-65% increases in paclitaxel AUC were observed in 4 of the 6 patients. Mean C(max) of ONT-093 was 9 microM (range 5-15 microM) which were 3- to 5-fold higher than in single agent studies of ONT-093. CONCLUSIONS: Doses of ONT-093 achieving serum concentrations associated with biological activity were well tolerated in combination with standard doses of paclitaxel. Toxicities of the combination in this schedule were mainly attributable to paclitaxel and dose-limiting toxicity was limited to febrile neutropenia. There was an apparent pharmacokinetic interaction between paclitaxel and ONT-093, possibly related in part to the excipient, Cremophor, present in the paclitaxel formulation. More... »

PAGES

311-315

References to SciGraph publications

  • 2001-04. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1997-06. Multidrug resistance: molecular mechanisms and clinical relevance in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x

    DOI

    http://dx.doi.org/10.1007/s10637-005-1439-x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1042192945

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/16012790


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "ATP Binding Cassette Transporter, Subfamily B, Member 1", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Alopecia", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents, Phytogenic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Arthralgia", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Therapy, Combination", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Imidazoles", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neutropenia", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Paclitaxel", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Polyethylene Glycols", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "BC Cancer Agency", 
              "id": "https://www.grid.ac/institutes/grid.248762.d", 
              "name": [
                "BC Cancer Agency, Vancouver, British Columbia, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chi", 
            "givenName": "Kim N.", 
            "id": "sg:person.01142252161.65", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "BC Cancer Agency", 
              "id": "https://www.grid.ac/institutes/grid.248762.d", 
              "name": [
                "BC Cancer Agency, Vancouver, British Columbia, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chia", 
            "givenName": "Stephen K.", 
            "id": "sg:person.0743651364.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743651364.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Ontogen Corporation, Solana Beach, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dixon", 
            "givenName": "Ross", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Ontogen Corporation, Solana Beach, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Newman", 
            "givenName": "Michael J.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Ontogen Corporation, Solana Beach, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wacher", 
            "givenName": "Vince J.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Stanford University", 
              "id": "https://www.grid.ac/institutes/grid.168010.e", 
              "name": [
                "Stanford University, Palo Alto, California, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sikic", 
            "givenName": "Branimir", 
            "id": "sg:person.01262727277.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262727277.82"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "BC Cancer Agency", 
              "id": "https://www.grid.ac/institutes/grid.248762.d", 
              "name": [
                "BC Cancer Agency, Vancouver, British Columbia, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gelmon", 
            "givenName": "Karen A.", 
            "id": "sg:person.01173252503.80", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s002800051053", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022009924", 
              "https://doi.org/10.1007/s002800051053"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1177/38.9.1974900", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031461172"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1177/38.9.1974900", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031461172"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/jnci/92.3.205", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032301848"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s002800000215", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035156827", 
              "https://doi.org/10.1007/s002800000215"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1074652722", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2001.19.12.2975", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1074835647"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1075014921", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1075201523", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1082375302", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1083187952", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2005-08", 
        "datePublishedReg": "2005-08-01", 
        "description": "BACKGROUND: ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg.\nMETHODS: Phase I pharmacokinetic trial of ONT-093 in doses from 300 to 500 mg administered before and after intravenous paclitaxel doses of 150 to 175 mg/m(2) repeated every 21 days. All patients received paclitaxel alone on cycle 1.\nRESULTS: 18 patients were enrolled onto 4 dose levels. Toxicity of the combination included neutropenia, arthralgia, myalgia, and peripheral neuropathy. Four of 6 patients receiving 500 mg doses of ONT-093 and paclitaxel at 175 mg/m(2) (dose level 4) had higher-grade neutropenia with cycle 2, with 1 patient experiencing febrile neutropenia. Plasma pharmacokinetic parameters of paclitaxel were unchanged between cycle 1 and 2 for dose levels 1 to 3, but at dose level 4, 45-65% increases in paclitaxel AUC were observed in 4 of the 6 patients. Mean C(max) of ONT-093 was 9 microM (range 5-15 microM) which were 3- to 5-fold higher than in single agent studies of ONT-093.\nCONCLUSIONS: Doses of ONT-093 achieving serum concentrations associated with biological activity were well tolerated in combination with standard doses of paclitaxel. Toxicities of the combination in this schedule were mainly attributable to paclitaxel and dose-limiting toxicity was limited to febrile neutropenia. There was an apparent pharmacokinetic interaction between paclitaxel and ONT-093, possibly related in part to the excipient, Cremophor, present in the paclitaxel formulation.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s10637-005-1439-x", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1094201", 
            "issn": [
              "0167-6997", 
              "1573-0646"
            ], 
            "name": "Investigational New Drugs", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "23"
          }
        ], 
        "name": "A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer", 
        "pagination": "311-315", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "c8fc80a9287137e22ad10277d50fa831a453b41cebf346383a4ecc7fa6058450"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "16012790"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "8309330"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s10637-005-1439-x"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1042192945"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s10637-005-1439-x", 
          "https://app.dimensions.ai/details/publication/pub.1042192945"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T10:53", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000351_0000000351/records_43235_00000000.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://link.springer.com/10.1007%2Fs10637-005-1439-x"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-005-1439-x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    216 TRIPLES      21 PREDICATES      57 URIs      39 LITERALS      27 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s10637-005-1439-x schema:about N00480a000bd4470ca16944f8b7221f96
    2 N04d57b2f3e6041f1ab2ea313b5baf4a6
    3 N06e7f42e63ca4c1da67d4bfc415151cc
    4 N0b3ec96e8f414b81ab84201057d57df2
    5 N16d74e407d5a4d2fb7082f8270ca5c05
    6 N1844f2745aed43e9956bf92d06efd697
    7 N1b778c6da75a4d38a3dc924b643934ca
    8 N2f1c6f2066df42a68f8167fa5a674b0b
    9 N408e01c5f1c64efb8f2c7c352509a8cd
    10 N41143c9a7a82406eb09ea807e22edec8
    11 N43dff09cbcb24a5da13fd93c6aa27ff9
    12 N4ddc3069757b47afba6b78ad951f37b2
    13 N512facca079342f482bc57f7c966b60d
    14 N540df02067224c7bbd5cc8934a03e1d0
    15 N5daf4e4625054b7487adf92a06dd4225
    16 N695836f75d8744b8aa3b1f3466679d26
    17 Nad999a2514684d098a0e1a8054dcc692
    18 Ncdcd97fad9864d9293c80aaf3ac7a85e
    19 anzsrc-for:11
    20 anzsrc-for:1115
    21 schema:author Nafa190d479b24374bb685006182d539e
    22 schema:citation sg:pub.10.1007/s002800000215
    23 sg:pub.10.1007/s002800051053
    24 https://app.dimensions.ai/details/publication/pub.1074652722
    25 https://app.dimensions.ai/details/publication/pub.1075014921
    26 https://app.dimensions.ai/details/publication/pub.1075201523
    27 https://app.dimensions.ai/details/publication/pub.1082375302
    28 https://app.dimensions.ai/details/publication/pub.1083187952
    29 https://doi.org/10.1093/jnci/92.3.205
    30 https://doi.org/10.1177/38.9.1974900
    31 https://doi.org/10.1200/jco.2001.19.12.2975
    32 schema:datePublished 2005-08
    33 schema:datePublishedReg 2005-08-01
    34 schema:description BACKGROUND: ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. Phase I trials of ONT-093 in normal human volunteers showed no dose-limiting toxicities at serum concentrations associated with biologic activity achieved with doses ranging from 300 to 500 mg. METHODS: Phase I pharmacokinetic trial of ONT-093 in doses from 300 to 500 mg administered before and after intravenous paclitaxel doses of 150 to 175 mg/m(2) repeated every 21 days. All patients received paclitaxel alone on cycle 1. RESULTS: 18 patients were enrolled onto 4 dose levels. Toxicity of the combination included neutropenia, arthralgia, myalgia, and peripheral neuropathy. Four of 6 patients receiving 500 mg doses of ONT-093 and paclitaxel at 175 mg/m(2) (dose level 4) had higher-grade neutropenia with cycle 2, with 1 patient experiencing febrile neutropenia. Plasma pharmacokinetic parameters of paclitaxel were unchanged between cycle 1 and 2 for dose levels 1 to 3, but at dose level 4, 45-65% increases in paclitaxel AUC were observed in 4 of the 6 patients. Mean C(max) of ONT-093 was 9 microM (range 5-15 microM) which were 3- to 5-fold higher than in single agent studies of ONT-093. CONCLUSIONS: Doses of ONT-093 achieving serum concentrations associated with biological activity were well tolerated in combination with standard doses of paclitaxel. Toxicities of the combination in this schedule were mainly attributable to paclitaxel and dose-limiting toxicity was limited to febrile neutropenia. There was an apparent pharmacokinetic interaction between paclitaxel and ONT-093, possibly related in part to the excipient, Cremophor, present in the paclitaxel formulation.
    35 schema:genre research_article
    36 schema:inLanguage en
    37 schema:isAccessibleForFree false
    38 schema:isPartOf N78e911ccd43c484b9e637167167413ba
    39 Nff316dfd7ba645d7b2d7b15dd9657612
    40 sg:journal.1094201
    41 schema:name A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer
    42 schema:pagination 311-315
    43 schema:productId N2558e4cd122c4d91ad6c9b778a1a650c
    44 N34f6a4bb1f874ab8be8c74692f745777
    45 N9b32a9a97a3e4b79bd5104cf4c68f1b8
    46 Nc08351b7fb0f4e6f8a58585fc1e9e2cd
    47 Nffa5a123ae074e62b18adaa8aee64092
    48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042192945
    49 https://doi.org/10.1007/s10637-005-1439-x
    50 schema:sdDatePublished 2019-04-11T10:53
    51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    52 schema:sdPublisher N5ce5e24e381141c5a7acacc136217d91
    53 schema:url https://link.springer.com/10.1007%2Fs10637-005-1439-x
    54 sgo:license sg:explorer/license/
    55 sgo:sdDataset articles
    56 rdf:type schema:ScholarlyArticle
    57 N00480a000bd4470ca16944f8b7221f96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    58 schema:name Polyethylene Glycols
    59 rdf:type schema:DefinedTerm
    60 N04d57b2f3e6041f1ab2ea313b5baf4a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    61 schema:name Antineoplastic Agents, Phytogenic
    62 rdf:type schema:DefinedTerm
    63 N06e7f42e63ca4c1da67d4bfc415151cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    64 schema:name ATP Binding Cassette Transporter, Subfamily B, Member 1
    65 rdf:type schema:DefinedTerm
    66 N0a9222c5f3c645f2a927e25da8e7314c rdf:first N93bc2d59591a48faa46eb59653f2ec2f
    67 rdf:rest Nf4a057f127ce46759bf22fc19f645a62
    68 N0b3ec96e8f414b81ab84201057d57df2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    69 schema:name Male
    70 rdf:type schema:DefinedTerm
    71 N16d74e407d5a4d2fb7082f8270ca5c05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    72 schema:name Female
    73 rdf:type schema:DefinedTerm
    74 N1844f2745aed43e9956bf92d06efd697 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    75 schema:name Drug Therapy, Combination
    76 rdf:type schema:DefinedTerm
    77 N1b778c6da75a4d38a3dc924b643934ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    78 schema:name Middle Aged
    79 rdf:type schema:DefinedTerm
    80 N2558e4cd122c4d91ad6c9b778a1a650c schema:name doi
    81 schema:value 10.1007/s10637-005-1439-x
    82 rdf:type schema:PropertyValue
    83 N2e0afff41587419d8236cbcae623ebb4 rdf:first sg:person.01262727277.82
    84 rdf:rest Nb1a17ac7d86b4cf7bc6ff22edd8ec3d5
    85 N2f1c6f2066df42a68f8167fa5a674b0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    86 schema:name Dose-Response Relationship, Drug
    87 rdf:type schema:DefinedTerm
    88 N32c8777af8604e9fa447ab166df1b983 rdf:first sg:person.0743651364.39
    89 rdf:rest Ned314d2eb7744bd9b8c744848ab32b77
    90 N34f6a4bb1f874ab8be8c74692f745777 schema:name nlm_unique_id
    91 schema:value 8309330
    92 rdf:type schema:PropertyValue
    93 N401782b79a934a07b298ab5186413d4f schema:name Ontogen Corporation, Solana Beach, California, USA
    94 rdf:type schema:Organization
    95 N408e01c5f1c64efb8f2c7c352509a8cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    96 schema:name Neoplasms
    97 rdf:type schema:DefinedTerm
    98 N41143c9a7a82406eb09ea807e22edec8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    99 schema:name Neutropenia
    100 rdf:type schema:DefinedTerm
    101 N43dff09cbcb24a5da13fd93c6aa27ff9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    102 schema:name Alopecia
    103 rdf:type schema:DefinedTerm
    104 N4a91ce97600b49ed9aedcd5e74083f12 schema:name Ontogen Corporation, Solana Beach, California, USA
    105 rdf:type schema:Organization
    106 N4ddc3069757b47afba6b78ad951f37b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    107 schema:name Paclitaxel
    108 rdf:type schema:DefinedTerm
    109 N512facca079342f482bc57f7c966b60d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    110 schema:name Adult
    111 rdf:type schema:DefinedTerm
    112 N540df02067224c7bbd5cc8934a03e1d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    113 schema:name Arthralgia
    114 rdf:type schema:DefinedTerm
    115 N5ce5e24e381141c5a7acacc136217d91 schema:name Springer Nature - SN SciGraph project
    116 rdf:type schema:Organization
    117 N5daf4e4625054b7487adf92a06dd4225 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Aged
    119 rdf:type schema:DefinedTerm
    120 N695836f75d8744b8aa3b1f3466679d26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Humans
    122 rdf:type schema:DefinedTerm
    123 N78e911ccd43c484b9e637167167413ba schema:volumeNumber 23
    124 rdf:type schema:PublicationVolume
    125 N7c773ea65b68406bbec52a41fbd234a6 schema:affiliation N4a91ce97600b49ed9aedcd5e74083f12
    126 schema:familyName Wacher
    127 schema:givenName Vince J.
    128 rdf:type schema:Person
    129 N93bc2d59591a48faa46eb59653f2ec2f schema:affiliation Na27e9fb8296a4afa9ce0c6134a14c769
    130 schema:familyName Newman
    131 schema:givenName Michael J.
    132 rdf:type schema:Person
    133 N9b32a9a97a3e4b79bd5104cf4c68f1b8 schema:name dimensions_id
    134 schema:value pub.1042192945
    135 rdf:type schema:PropertyValue
    136 Na27e9fb8296a4afa9ce0c6134a14c769 schema:name Ontogen Corporation, Solana Beach, California, USA
    137 rdf:type schema:Organization
    138 Nad999a2514684d098a0e1a8054dcc692 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Antineoplastic Agents
    140 rdf:type schema:DefinedTerm
    141 Nafa190d479b24374bb685006182d539e rdf:first sg:person.01142252161.65
    142 rdf:rest N32c8777af8604e9fa447ab166df1b983
    143 Nb1a17ac7d86b4cf7bc6ff22edd8ec3d5 rdf:first sg:person.01173252503.80
    144 rdf:rest rdf:nil
    145 Nbcfb51ca73bb479c9d6c84e327b75c68 schema:affiliation N401782b79a934a07b298ab5186413d4f
    146 schema:familyName Dixon
    147 schema:givenName Ross
    148 rdf:type schema:Person
    149 Nc08351b7fb0f4e6f8a58585fc1e9e2cd schema:name readcube_id
    150 schema:value c8fc80a9287137e22ad10277d50fa831a453b41cebf346383a4ecc7fa6058450
    151 rdf:type schema:PropertyValue
    152 Ncdcd97fad9864d9293c80aaf3ac7a85e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Imidazoles
    154 rdf:type schema:DefinedTerm
    155 Ned314d2eb7744bd9b8c744848ab32b77 rdf:first Nbcfb51ca73bb479c9d6c84e327b75c68
    156 rdf:rest N0a9222c5f3c645f2a927e25da8e7314c
    157 Nf4a057f127ce46759bf22fc19f645a62 rdf:first N7c773ea65b68406bbec52a41fbd234a6
    158 rdf:rest N2e0afff41587419d8236cbcae623ebb4
    159 Nff316dfd7ba645d7b2d7b15dd9657612 schema:issueNumber 4
    160 rdf:type schema:PublicationIssue
    161 Nffa5a123ae074e62b18adaa8aee64092 schema:name pubmed_id
    162 schema:value 16012790
    163 rdf:type schema:PropertyValue
    164 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    165 schema:name Medical and Health Sciences
    166 rdf:type schema:DefinedTerm
    167 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    168 schema:name Pharmacology and Pharmaceutical Sciences
    169 rdf:type schema:DefinedTerm
    170 sg:journal.1094201 schema:issn 0167-6997
    171 1573-0646
    172 schema:name Investigational New Drugs
    173 rdf:type schema:Periodical
    174 sg:person.01142252161.65 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
    175 schema:familyName Chi
    176 schema:givenName Kim N.
    177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
    178 rdf:type schema:Person
    179 sg:person.01173252503.80 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
    180 schema:familyName Gelmon
    181 schema:givenName Karen A.
    182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80
    183 rdf:type schema:Person
    184 sg:person.01262727277.82 schema:affiliation https://www.grid.ac/institutes/grid.168010.e
    185 schema:familyName Sikic
    186 schema:givenName Branimir
    187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262727277.82
    188 rdf:type schema:Person
    189 sg:person.0743651364.39 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
    190 schema:familyName Chia
    191 schema:givenName Stephen K.
    192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743651364.39
    193 rdf:type schema:Person
    194 sg:pub.10.1007/s002800000215 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035156827
    195 https://doi.org/10.1007/s002800000215
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1007/s002800051053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022009924
    198 https://doi.org/10.1007/s002800051053
    199 rdf:type schema:CreativeWork
    200 https://app.dimensions.ai/details/publication/pub.1074652722 schema:CreativeWork
    201 https://app.dimensions.ai/details/publication/pub.1075014921 schema:CreativeWork
    202 https://app.dimensions.ai/details/publication/pub.1075201523 schema:CreativeWork
    203 https://app.dimensions.ai/details/publication/pub.1082375302 schema:CreativeWork
    204 https://app.dimensions.ai/details/publication/pub.1083187952 schema:CreativeWork
    205 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
    206 rdf:type schema:CreativeWork
    207 https://doi.org/10.1177/38.9.1974900 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031461172
    208 rdf:type schema:CreativeWork
    209 https://doi.org/10.1200/jco.2001.19.12.2975 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074835647
    210 rdf:type schema:CreativeWork
    211 https://www.grid.ac/institutes/grid.168010.e schema:alternateName Stanford University
    212 schema:name Stanford University, Palo Alto, California, USA
    213 rdf:type schema:Organization
    214 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
    215 schema:name BC Cancer Agency, Vancouver, British Columbia, Canada
    216 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...